Linked Life Data

2687193

Source:http://linkedlifedata.com/resource/pubmed/id/2687193

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1990-1-25
pubmed:abstractText
The authors undertook a double-blind parallel group comparative study of 80 adult patients to examine the efficacy, safety, and tolerance of ioversol and sodium/meglumine diatrizoate in patients undergoing computed body tomography (CT). All procedures were considered diagnostic, although the scan quality of four procedures enhanced with sodium/meglumine diatrizoate was rated fair. Both contrast media induced clinically insignificant postprocedure decreases in mean systolic and diastolic blood pressure. There were no statistically significant differences between the two contrast media in their effects on these or other vital signs. Ioversol was better tolerated, as evidenced by significantly lower pain and heat scores. There was a remarkable difference in adverse side effects induced by ioversol (n = 0) and sodium/meglumine diatrizoate (n = 14 [35%], including six of moderate severity). Ioversol is a safe and effective nonionic contrast agent for contrast-enhanced body CT.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0020-9996
pubmed:author
pubmed:issnType
Print
pubmed:volume
24 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S35-8
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Computed body tomography with a new nonionic contrast agent. Comparison of ioversol with sodium/meglumine diatrizoate.
pubmed:affiliation
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial